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Abstract
Background: Psoriasis is an immune-mediated disease characterized by aberrant epidermal differentiation, surface scale
formation, and marked cutaneous inflammation. To better understand the pathogenesis of this disease and identify
potential mediators, we used whole genome array analysis to profile paired lesional and nonlesional psoriatic skin and skin
from healthy donors.
Methodology/Principal Findings: We observed robust overexpression of type I interferon (IFN)–inducible genes and
genomic signatures that indicate T cell and dendritic cell infiltration in lesional skin. Up-regulation of mRNAs for IFN-a
subtypes was observed in lesional skin compared with nonlesional skin. Enrichment of mature dendritic cells and 2 type I
IFN–inducible proteins, STAT1 and ISG15, were observed in the majority of lesional skin biopsies. Concordant
overexpression of IFN-c and TNF-a–inducible gene signatures occurred at the same disease sites.
Conclusions/Significance: Up-regulation of TNF-a and elevation of the TNF-a–inducible gene signature in lesional skin
underscore the importance of this cytokine in psoriasis; these data describe a molecular basis for the therapeutic activity of
anti–TNF-a agents. Furthermore, these findings implicate type I IFNs in the pathogenesis of psoriasis. Consistent and
significant up-regulation of type I IFNs and their associated gene signatures in psoriatic skin suggest that type I IFNs may be
potential therapeutic targets in psoriasis treatment.
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Introduction
Psoriasis is a debilitating skin disease that affects approximately
2% to 3% of the US population. Although originally viewed as a
disease primarily caused by dysfunction of keratinocytes, psoriasis
is now recognized as a complicated immune system disorder that
involves the interplay of innate immunity and adaptive immune
response [1–3]. Epidermal hyperplasia; aberrant keratinocyte
proliferation and differentiation; angiogenesis; infiltration of T
lymphocytes; dendritic cells and neutrophils; and elements of
innate immunity are all thought to contribute to the pathogenesis
of the disease [4,5]. Currently, the biologics approved by the US
Food and Drug Administration to treat psoriasis target either T
cells or TNF-a. Alefacept (AmeviveH, Astellas Pharma US, Inc.)
inhibits CD2 cell binding to lymphocyte function–associated
antigen 3 (LFA-3). Efalizumab (RaptivaH, Genentech, Inc., South
San Francisco, CA) binds to the CD11a subunit of LFA-1, thereby
preventing LFA-1 from binding to intercellular adhesion molecule
1. Etanercept (EnbrelH, Immunex Corporation, Thousand Oaks,
CA), infliximab (RemicadeH, Centocor, Inc., Malvern, PA), and
adalimumab (HumiraH, Abbott Laboratories, North Chicago, IL)
are all TNF-a blockers and have clinical response rates that range
from 25% to 50% in psoriatic patients. Despite the success of anti–
TNF-a therapies, the involvement of TNF-a in disease pathogen-
esis is not yet fully understood.
The limited clinical response associated with some currently
available therapeutics and uncertainties regarding the complexity
of psoriasis raise the possibility of other factors being implicated in
the pathogenesis. IL-12/IL-23 has been shown to be involved in
psoriasis. IL-23 is a key inducer of IFN-c synthesis in T cells. The
activation of IFN-c signaling in lesional skin of psoriatic patients
has been confirmed by genomic profiling [6]. Increased expression
of mRNAs encoding p19 and p40 subunits of IL-23 has been
found in lesional skin of psoriatic patients [7]. In clinical trials of
psoriasis treatments, targeting of IL-12/IL-23 has resulted in
significant clinical benefits for patients. Administration of an anti–
p40 antibody to a small number of psoriatic patients showed
significantly improved clinical activity [8].
Recently, Mee et al showed that IL-1b was constitutively
expressed by keratinocytes in vivo and overexpressed in lesional
skin [9]. Boniface et al demonstrated that oncostatin M (OSM), a
member of the IL-6 family of cytokines, was a potent keratinocyte
activator similar to TNF-a, IL-1, IL-17, and IL-22. They also
showed that OSM was associated with cutaneous inflammatory
responses [10]. IL-22, an effector cytokine mainly produced by T
cells, and IL-17 were found to mediate cross talk between the
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functions in host defense and the pathogenesis of psoriasis [11]. It
remains to be seen whether drugs directed at these potential
therapeutic targets translate to meaningful clinical response rates
in psoriasis patients.
Giventhelimitedbenefitandlackofmechanisticunderstandingof
currently approved TNF-a blockers, as well as the preliminary
nature of the studies of additional molecules, we wanted to identify
other factors that might contribute to the pathogenesis of disease.
Such factors could represent additional therapeutic opportunities.
For the first time, we used the AffymetrixH whole genome U133 plus
v2.0 array platform to profile a large panel of paired lesional and
nonlesional skin biopsies from psoriatic patients and to compare the
skin profiles from sex- and age-matched healthy donors.
Results
The IFNa/b signaling pathway is significantly activated in
lesional skin of psoriatic patients
To identify characteristics of cutaneous alterations specific to
psoriasis, we used an Affymetrix human genome U133 plus v2.0
array platform to profile skin samples from donors classified as
normal (n=21), 26 paired nonlesional and lesional skin biopsies
from 24 psoriatic patients, and lesional skin biopsies from an
additional 5 psoriatic patients (the paired nonlesional skin either
did not yield sufficient cRNA for hybridization, or scanned arrays
had high scaling factors that were more than 3-fold above the
average). Probe-level summaries were calculated using the GC-
RMA normalization algorithm in Stratagene’s ArrayAssistH Lite
software package. Significance analysis of microarrays with control
of the false discovery rate (see Materials and Methods) was used to
select differentially regulated genes in psoriasis (pairwise compar-
ison among lesional and nonlesional skin, lesional skin and skin
from healthy donors, and nonlesional and skin from healthy
donors). Probe sets with $2-fold change and q value#0.05 were
considered to be differentially regulated.
Overall, we observed that 1408 probe sets were up-regulated and
1465 probe sets were down-regulated in lesional skin compared with
nonlesional skin. Although the number of down-regulated genes
outnumbered the up-regulated genes in lesional skin, the up-
regulated genes generally showed a much larger magnitude of
differential regulation overall. For example, 318 probe sets were up-
regulated $4-fold in lesional skin, whereas only 84 probe sets were
down-regulated by $4-fold in lesional skin. Subsequently, our
analysis focused mostly on the up-regulated genes.
Additionally, we observed that 460 probe sets were up-regulated
and 489 probe sets were down-regulated in nonlesional skin
compared with skin from healthy donors. The genes differentially
regulated in nonlesional skin are mostly distinct from those altered
in lesional skin. Figure 1 shows a Venn diagram of the probe sets
altered in lesional skin and nonlesional skin. Only 36 of the 1408
up-regulated probe sets in lesional skin were also up-regulated in
nonlesional skin. Similarly, only 43 of the 1465 probe sets down-
regulated in lesional skin were also down-regulated in nonlesional
skin. Taken together, these data suggest that the molecular events
and biological changes from nonlesional skin to lesional skin are
mainly distinct from the differences between normal and nonle-
sional skin.
Of the genes up-regulated in lesional skin, CD4, CD69, IL-7R,
and IL-2Rc are T cell markers; CXCL9, CXCL10, CXCL11,
CCL18, CCL19, and CCR7 are involved in T cell trafficking and
recruitment; LAMP3, CD83, CD163, CD53, and CD24 are
dendritic cell surface markers; IL-1b, IRAK2, IL-1F5, IL-1F6, and
IL-1F9 are IL-1–inducible genes; IL-8 is a neutrophil-chemotactic
factor whose production can be induced by IL-1, TNF-a and OSM.
The strong overexpression of S100A family members and DEFB4 in
lesional skin could result from both neutrophil infiltration and
keratinocyte activation. Overall, these observations agree with the
well-known presence of T cells, dendritic cells, and neutrophils in
lesional skin of psoriatic patients. It is also worth noting that IL-8
mRNA is highly up-regulated in lesional skin, whereas it is slightly
down-regulated innonlesional skin compared with skinfrom healthy
donors (Table S1). This observation suggests an increase of
neutrophil activity in lesional skin of psoriatic patients.
Many of the genes downregulated in nonlesional skin compared
to normal skin are transcription factors such as JUN, JUNB,
FOSB, ATF3, NR4A2, PER1, EGR1, MAFF (Table S3). This
finding suggests that nonlesional skin, although overtly normal, has
readily identifiable alterations at the transcript level. In contrast,
the most downregulated genes in lesional skin compared to
nonlesional skin include genes that encode structural, cell adhesion
and tight junction proteins such as CLDN8, KRT1B,
CNTNAP3B, PCDH21, PAPLN; immune response genes such
as IL1F7, CCL27, F3; and genes involved in signaling pathways
such as WIF1, ADRB2, TIMP3 (Table S2).
To identify the signaling pathways altered in psoriasis, we
performed an analysis using the GeneGo MetaCore pathway and
network approach (see Materials and Methods). Overall, 22
signaling pathways were activated and 37 signaling pathways were
suppressed (P,0.05) in lesional skin compared with nonlesional
skin. All the putative signaling pathways activated were cytokine-
and chemokine-mediated signaling pathways or were involved in
immune responses. For example, in agreement with the literature
[10,12], IFN-c, TNF-a, and OSM signaling pathways were
activated in lesional skin of psoriatic patients. Of all the signaling
pathways altered between lesional and nonlesional skin, the IFN-
Figure 1. Probe sets found to be altered using microarray
analysis. Venn diagram illustrates the number of probe sets that show
altered expression at the mRNA level in all three combinations of
lesional skin, nonlesional skin, and skin from healthy donors. Values
shaded in red indicate the number of probe sets significantly up-
regulated; values shaded in green indicate the number of probe sets
significantly down-regulated. The intersecting regions represent probe
sets that are common to the specific comparisons.
doi:10.1371/journal.pone.0002737.g001
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pathway (P=6.6610
226; Figure 2). Components of the pathway,
such as IFNAR1, IFNAR2, STAT1, IRF1, MPL, ISG15, and
IFI6, were all significantly overexpressed in lesional skin compared
with nonlesional skin of psoriatic patients. WNT, PTEN, PDGF,
ESR1 and several cell adhesion pathways are among the most
significantly suppressed pathways in lesional skin compared to
nonlesional skin of psoriatic patients.
Type I IFN–inducible genes are overexpressed in lesional
skin of psoriatic patients
To determine the prevalence and magnitude of the overex-
pression of type I IFN–inducible genes in psoriasis, we first carried
out ex vivo stimulation of healthy donor whole blood and in vitro
stimulation of normal human keratinocytes with different
members of the type I IFN family (see Materials and Methods
and Supplemental Material) to identify type I IFN–inducible
genes. We observed 689 probe sets (about 1.3% of all probe sets on
the Affymetrix human genome U133 plus v2.0 array) that were
uniformly up-regulated in whole blood following stimulation for
4 hours by 1 of the 9 IFN-a subtypes or by IFN-b. A total of 336
probe sets were down-regulated by IFN-a or IFN-b in the same
experiment. In keratinocytes, many of these genes (i.e., IFIT1,
IFIT2, IFIT3, RSAD2, ISG15, MX1, DDX58, IFI44, IFI44L)
were also up-regulated following in vitro stimulation by IFN-a2a,
an IFN-a subtype, or by leukocyte IFN (a mixture of type I IFNs).
The top 50 probes upregulated by leukocyte IFN are listed in
Table S4. The probes upregulated by IFN-a2a are similar to those
by leukocyte IFN (data not shown).
From the list of probe sets that were identified to be type I IFN–
inducible from the ex vivo stimulation studies, we identified 164 of
1408 probe sets (11.7%) that were up-regulated in lesional skin
compared with nonlesional skin as being type I IFN-inducible.
Using Fisher exact test (1-tailed t test), the observed overexpression
of type I IFN–inducible genes in lesional skin of psoriatic patients
was found to be statistically significant (P,0.0001). We also
observed that 19 of the top 100 (Table S1) most up-regulated
probe sets in lesional skin were type I IFN–inducible genes,
indicating an enrichment of type I IFN–inducible genes among the
most overexpressed genes in lesional skin of psoriatic patients.
Table 1 lists the top 50 most up-regulated type I IFN–inducible
genes (expressed sequence tags [ESTs] and hypothetical proteins
are excluded from the list) in lesional skin of psoriatic patients.
Next, we asked whether type I IFN–inducible genes are also
significantly overexpressed in nonlesional skin of psoriatic patients
compared with skin from normal donors. Of all the probe sets that
are overexpressed in nonlesional skin of psoriatic patients
compared with skin from healthy donors, only 1% (5 probe sets)
are type I IFN–inducible. The overexpression of type I IFN–
inducible genes was not significant (Fisher exact test [2-tailed t
test]; P=0.581) in nonlesional skin of psoriatic patients. From
Table 1, we observe that for those genes up-regulated in lesional
skin compared with nonlesional skin in psoriatic patients, nearly all
are expressed at similar levels in nonlesional skin compared with
Figure 2. Type I IFN signaling pathway activated in lesional skin of psoriatic patients. Pathway image was generated with GeneGo’s
MetaCore integrated software suite. Individual symbols within the image represent well–characterized proteins or protein complexes. Arrows linking
the proteins represent the stimulatory, inhibitory, or interactive effect of the protein on the target protein. Thermometers adjacent to the individual
symbols represent relative expression levels (red indicates overexpression; blue indicates underexpression) of transcripts that encode the protein (or
protein complex) within the particular pathway.
doi:10.1371/journal.pone.0002737.g002
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PLoS ONE | www.plosone.org 5 July 2008 | Volume 3 | Issue 7 | e2737skin from healthy donors (several genes [eg, RGS1 and SPTLC2]
are down-regulated in nonlesional skin compared with skin from
healthy donors). This observation was also confirmed by pathway
analysis in which the IFN-a/b signaling pathway was not
significantly altered in nonlesional skin compared with skin from
healthy donors (P value close to 1). Figure 3 shows the relative
expression of 3 type I IFN–inducible genes (HPSE, OASL, and
HERC6) and 1 gene that is not IFN–inducible (SERPINB4) in
lesional skin compared with nonlesional skin, and in nonlesional
skin compared with skin from healthy donors. The expression of
these genes in lesional skin compared with nonlesional skin is
statistically significant, and on average, 12- and 250-fold higher,,
whereas the mRNA levels of these genes remain unaltered in
nonlesional skin compared with skin from healthy donors.
Figure 4A shows a heat map of unsupervised hierarchical
clustering of the 164 up-regulated type I IFN–inducible probe sets
in all lesional and nonlesional skin from psoriatic patients and skin
from healthy donors. These samples segregate into 2 large clusters:
one composed of all lesional skin biopsies and the other composed
of all normal and nonlesional skin samples. This observation
demonstrates that the magnitude of the overexpression of type I
IFN–inducible genes in lesional skin is distinct from that in
nonlesional skin or skin from healthy donors.
Figure 4B shows the principal components analysis (PCA) plot
of the same samples shown in Figure 4A using the same 164 type I
IFN–inducible probe sets. PCA is a mathematical calculation that
reduces the dimensionality of the data set so that each individual
sample can be viewed in a 2- or 3-dimensional plot. Skin biopsies
from healthy donors and nonlesional skin biopsies are mostly
clustered together, which suggests that they have comparable level
of expression of type I IFN–inducible genes. Furthermore, the
analysis shows that the majority of lesional skin biopsies clearly
separate from normal and nonlesional skin biopsies. This indicates
that most of these patients had overexpression of the type I IFN–
inducible genes, and that was distinct from those in the other 2
groups. Three lesional skin biopsies are close to the nonlesional
skin and skin from healthy donors group in the PCA plot. These 3
samples were from the 3 psoriatic patients that had weaker
overexpression of type I IFN–inducible genes compared with the
rest of the psoriatic patients in the study.
We then asked whether the observed overexpression of the type
I IFN–inducible genes in psoriatic patients from microarray
studies could be confirmed by a second platform. We used a
BioMark
TM 48.48 dynamic array, a high throughput TaqMan
quantitative real-time polymerase chain reaction (QRT-PCR)–
based technology from Fluidigm, to analyze the profiled samples.
Figure 3. Relative expression of selected genes. Shown are three type I IFN–inducible genes (HPSE, OASL, and HERC6) and 1 gene that is not
type I IFN–inducible (SERPINB4) in lesional skin (LS) compared with nonlesional skin (NS) in psoriatic patients, and in NS compared with skin from
healthy donors (NN) based on microarray data. The fold changes of these genes in LS are compared with their paired NS, and NS is compared with
the average of 21 NN controls. The horizontal bars represent the average fold change. The P values for the relative expression of HPSE, OASL, HERC6,
and SERPINB4 between NS and NN, and between LS and NS are (listed in pairs): 0.468, ,0.00001; 0.376, ,0.00001; 0.03, ,0.00001; 0.0002, ,0.00001,
respectively.
doi:10.1371/journal.pone.0002737.g003
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PLoS ONE | www.plosone.org 6 July 2008 | Volume 3 | Issue 7 | e2737Lesional and nonlesional skin biopsy pairs from 18 psoriatic
patients, along with pooled biopsies from healthy donors, were
assayed for the relative expression of mRNA of 40 genes (29 genes
were type I IFN–inducible; the other 11 genes were among the
most up-regulated in lesional skin of psoriatic patients). These
genes were selected based on their prevalence and magnitude of
overexpression in lesional skin biopsies. The overexpression of all
genes in lesional skin was confirmed by TaqMan QRT-PCR. In
the majority of the genes, good correlation between microarray
and TaqMan assays was observed [13]. Overall, these observa-
tions further substantiate that type I IFN–inducible genes are
significantly overexpressed in lesional skin of psoriatic patients but
not in nonlesional skin of patients or skin from normal donors.
Type I IFNs, IFNAR1, and IFNAR2 mRNA are up-regulated
in lesional skin as compared with nonlesional skin and
skin from healthy donors
Given that we observed significant overexpression of type I
IFN–inducible genes in lesional skin of psoriatic patients, we
wanted to characterize the type I IFNs that may be responsible. As
reported previously, we were not able to detect IFN-a proteins in
skin from healthy donors or stable psoriatic skin [14]. Schmid et al
[15] were able to use in situ hybridization to weakly detect IFN-a
mRNA throughout the hyperkeratotic epidermis. However, they
could not detect IFN-b, most likely because of the sensitivity
limitation in their measurements.
Figure 4. Clustering of up-regulated genes. A, Hierarchical clustering of all psoriasis samples profiled (blue: 21 normal, black: 23 paired
nonlesional, and pink: 26 lesional skin from psoriatic patients; and red: 5 unpaired lesional skin from 3 psoriatic patients) using the 164 up-regulated
type I IFN–inducible probe sets in lesional skin compared with those in mostly paired nonlesional skin. Each row corresponds to a single probe set;
each column corresponds to a single sample. Branch lengths indicate the degree of similarity with joined samples, with a longer branch indicating a
less similarity between joined samples. Red represents up-regulation vs control (ie, average expression of 21 normal samples), and green represents
down-regulation vs control. B, 3-dimensional PCA plot of all psoriasis samples profiled using the 164 up-regulated type I IFN–inducible probe sets in
lesional skin compared with those in mostly paired nonlesional skin. Each point represents 1 sample (blue: skin from healthy donors, black:
nonlesional skin, red: lesional skin).
doi:10.1371/journal.pone.0002737.g004
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PLoS ONE | www.plosone.org 7 July 2008 | Volume 3 | Issue 7 | e2737We used the TaqMan Low Density Array (TLDA) technology (a
TaqMan QRT-PCR–based assay) from Applied Biosystems to
measure the mRNA level of type I IFN family members in paired
lesional skin and nonlesional skin from 18 different psoriatic
patients, together with RNA from 2 of the healthy donor skin
biopsies. Genes that represent 9 IFN-a subtypes (1, 2, 5, 6, 7, 8, 14,
17 and 21; the primers for 4 other IFN-a subtypes were not
available), IFN-b,- k,- v, IFNAR1, and IFNAR2 were printed on
the array. The relative overexpression of mRNA of 9 IFN-a
subtypes in lesional skin compared with either nonlesional skin or
skin from healthy donors is shown in Figure 5A. With the
exception of IFN-a5( P,0.001), none of the mRNA levels of the
IFN-a subtypes were significantly altered in nonlesional skin
compared with skin from healthy donors. However, all of these
IFN-a subtypes were up-regulated at the mRNA level in lesional
skin compared with that in skin from healthy donors. The
overexpression of IFN-a1, IFN-a5, IFN-a8, IFN-a14, IFN-a17,
IFN-a21 was statistically significant (P,0.05). The overexpression
Figure 5. Relative expression and median fold changes of select mRNAs. Selected mRNAs include (A) Type I IFN-a subtypes (box plot), (B)
other Type-I IFNs, and (C) IFN-a receptors in lesional skin (LS) or nonlesional skin (NS) compared with skin from healthy donors (NN). Horizontal bars
represent median fold change. Black points: relative fold change in NS vs NN (NS/NN); Red points: relative fold change in LS vs NN (LS/NN). The P
values for the overexpression of these genes in NS or LS vs NN (listed in pairs) are as follows: IFN-a1, 0.303, ,0.001; IFN-a2, 0.389, 0.072; IFN-a5,
,0.001, 0.002; IFN-a6, 0.664, 0.093; IFN-a7, 0.586, 0.077; IFN-a8, 0.430, 0.049; IFN-a14, 0.224, 0.049; IFN-a17, 0.552, 0.0203; IFN-a21, 0.113, 0.003; IFN-b,
0.255, 0.022; IFN-k, 0.03, ,0.001; IFN-v, 0.516, 0.049; IFNAR1, 0.192, ,0.001; IFNAR2, ,0.001, ,0.001, respectively.
doi:10.1371/journal.pone.0002737.g005
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and –v) in lesional skin compared with nonlesional skin or skin from
healthy donors is shown in Figure 5B. The alterations of IFN-b and
IFN-v mRNAs in nonlesional skin were not significant. However,
these mRNAs were significantly up-regulated in lesional skin
compared with skin from healthy donors (P=0.022 and P=0.049,
respectively). IFN-k mRNA was up-regulated by approximately 1.6-
fold (median fold change) in nonlesional skin (P=0.03), and was
sharply up-regulated by 62.6-fold (median fold change) in lesional
skin compared with skin from healthy donors (P,0.001). Further-
more, the receptors for type I IFNs, IFNAR1 and IFNAR2, were
alsosignificantly overexpressed inlesional skinof psoriatic patientsat
the transcript level (P,0.001; Figure 5C). Although IFNAR2 up-
regulation was significant in nonlesional skin, up-regulation of
IFNAR1 was not (Figure 5C). Collectively, these data provided
evidence that mRNA levels for most type I IFN family members
were comparable between nonlesional skin and skin from healthy
donors (with the exception of IFN-a5a n dI F N - k) and were
significantly increased in lesional skin of psoriatic patients.
Co-overexpression of type I, type II IFN, and TNF-a and
their gene signatures in lesional skin of psoriatic patients
T cells contribute to the development of diseased skin in
psoriasis and to the epidermal hyperproliferation in genetically
predisposed individuals through the secretion of Th1 cytokines.
Since biologics that target T cells and TNF-a show clinical benefit
in psoriasis, we addressed the involvement of IFN-c and TNF-a in
the pathogenesis of the disease. As mentioned earlier, we observed
the activation of both the IFN-c and TNF-a signaling pathways in
lesional skin of psoriatic patients.
We used TLDA to measure the mRNA levels of IFN-c,
IFNGR1, IFNGR2 and TNF-a in lesional and nonlesional skin
from psoriatic patients and compared them with those from
healthy donors. Unlike what was found with type I IFNs, the
mRNA levels of IFN-c, IFNGR1, IFNGR2, and TNF-a were
significantly overexpressed in nonlesional skin compared with skin
from healthy donors (Figure 6; P=0.02, P,0.001, P,0.001 and
P,0.001 respectively). These genes were further up-regulated in
lesional skin compared with either nonlesional skin (P=0.04,
P=0.01, P=0.001 and P=0.007 respectively) or skin from
healthy donors (P,0.001 for all; Figure 6). These results show
that expression of mRNA for IFN-c and TNF-a is different from
that of type I IFN family members.
The ex vivo stimulation of healthy donor whole blood and in
vitro stimulation of keratinocytes with IFN-c and TNF-a was used
to identify genes induced by these cytokines. A total of 304 and
234 probe sets were up-regulated by IFN-c and TNF-a,
respectively, by at least 2-fold in the whole blood of all 4 donors
challenged for 4 hours. Of the 1408 probe sets that were up-
regulated in lesional skin compared with nonlesional skin of
psoriatic patients, 106 and 35 of them were IFN-c and TNF-a–
inducible, respectively (Figure 7). Fisher exact test (1-tailed t test)
indicated that overexpression of IFN-c and TNF-a–inducible
genes in lesional skin was significant (P,0.0001).
Type I IFN, IFN-c, and TNF-a–inducible probe sets identified in
the ex vivo study allowed us to identify the type I IFN, IFN-c,a n d
TNF-a–inducible genes in each lesional skin biopsy compared with
paired nonlesional biopsies that were up-regulated by at least 2-fold.
Figure 8A shows the number of type I IFN, IFN-c,a n dT N F - a–
inducible genes up-regulated in each of the 26 paired lesional and
nonlesional skin biopsies. The numbers of IFN-c and TNF-a–
inducible genes in a given lesional skin biopsy positively correlated
with the number of type I IFN–inducible genes in the same sample.
This observation was confirmed by the strong correlation in the
coactivation of these 3 sets of genes with correlation coefficients of at
least 0.918 in all 3 pairwise comparisons (Figure 8A) and by
significantPvalueswhencomparingtheup-regulationofany2ofthe
3 sets of genes in lesional skin compared with nonlesional skin
(P,0.001 for all 3 comparisons; Figure 8B).
A similar analysis was carried out for genes that were down-
regulated in lesional skin compared with the nonlesional skin of
psoriatic patients (Figure 7). Of the 1465 probe sets down-
regulated in lesional skin, only 17, 5, and 5 of them were type I
IFN, IFN-c, and TNF-a inducible.
Somewhat surprisingly we found that although mRNAs of IFN-c
and TNF-a were found to be up-regulated in nonlesional skin of
psoriatic patients when compared with those from healthy donors,
we did not find that IFN-c or TNF-a–inducible genes were
significantly overexpressed in nonlesional skin (data not shown).
The up-regulation of mRNAs of type I IFNs, IFN-c, and TNF-a,
together with the corresponding up-regulation of their respective
gene signatures in psoriatic lesional skin, suggests the presence of
type I IFNs, IFN-c, and TNF-a protein and active signaling in skin
lesions. In contrast, the elevated expression of mRNAs of IFN-c and
TNF-a in nonlesional skin does not result in corresponding up-
regulation of IFN-c or TNF-a–inducible genes. This suggests that
IFN-c and TNF-a proteins are not made in nonlesional skin or that
other signaling molecules might have inhibitory effects on the IFN-c
and TNF-a pathways in nonlesional skin of psoriatic patients.
Immunohistochemical analysis of psoriatic, nonlesional
skin, and skin from healthy donors
To determine whether the highly overexpressed type I IFN–
inducible genes in psoriatic skin gave rise to similar changes in the
expression of the proteins, immunohistochemical analyses were
Figure 6. Changes in expression of TNF-a, IFN-c, and IFN-c
receptors. Relative expression of mRNA and median fold changes of in
lesional skin (LS), or nonlesional skin (NS) compared with skin from
healthy donors (NN) are shown. The averages of the relative mRNA
levels of these cytokine and their receptors in NN from 2 donors were
scaled to 1 based on TaqMan QRT-PCR assays. The horizontal bars
represent the median fold change. Black points: the relative fold change
of mRNA in NS compared with NN; Red points: the relative fold change
of mRNA in LS compared with NN. The P values for the overexpression
of these individual genes in NS or LS compared with NN (listed in pairs)
are as follows: IFN-c, 0.02, ,0.001; IFNGR1, ,0.001, ,0.001; IFNGR2,
,0.001, ,0.001; TNF-a, ,0.001, ,0.001, respectively.
doi:10.1371/journal.pone.0002737.g006
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proteins, STAT1 and ISG15, in skin from the same patients and
the same biopsy samples that underwent whole genome array
analysis as described above. Furthermore, immunohistochemical
characterization of the cellular infiltrates (pDCs, mDCs, and CD4
+
Figure 8. Co-overexpression of type I IFN, IFN-c and TNF-a–
inducible genes. Paired lesional and nonlesional skin of psoriatic
patients was analyzed with Affymetrix GenechipH. The type I IFN, IFN-c
and TNF-a–inducible genes were selected based on healthy donor
whole blood ex vivo stimulation with these cytokines. A probe set with
fold change of $2 in lesional skin compared with its paired nonlesional
skin is considered overexpressed in the specific lesional skin. A, The
number of up-regulated type I IFN–, IFN-c– and TNF-a–inducible genes
in lesional skin compared with paired nonlesional skin shows a strong
correlation (r=Pearson’s correlation coefficient) from pairwise compar-
isons. B, The numbers of type I IFN–, IFN-c– and TNF-a–inducible genes
in lesional skin compared with nonlesional skin are significantly
different as evident from pairwise comparisons. The horizontal bars
represent the median value for each group.
doi:10.1371/journal.pone.0002737.g008
Figure 7. Probe sets common to lesions and ex vivo
stimulation. Venn diagrams illustrating both the number of probe
sets that are altered by type I IFN, IFN-c, and TNF-a in ex vivo
stimulation of whole blood from healthy donors (left circles) and probe
sets that are altered in lesional skin compared with nonlesional skin
(right circles). Red numbers: probe sets that show increased expression
with cytokine treatment or compared with nonlesional skin baseline.
Green numbers: probe sets that show decreased expression with
cytokine treatment or compared with nonlesional skin baseline. The
intersecting regions represent the probe sets that are common to both
comparisons.
doi:10.1371/journal.pone.0002737.g007
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cell types and inflammatory cells in the biopsies of lesional versus
nonlesional and skin from healthy donors. In all patients with
evaluable biopsy pairs, lesional skin contained increased numbers
of CD4
+ cells, as well as significant up-regulation of STAT1 and
ISG15 protein in the epidermis and dermis when compared with
nonlesional biopsies. Of the 16 pairs of lesional and nonlesional
skin biopsies, 6 pairs showed increased numbers of pDCs, and 9
pairs showed increased numbers of mDCs in lesional skin
compared with nonlesional skin. Although nonlesional skin
appeared grossly normal, there were often microscopic morpho-
logical changes that included low numbers of infiltrating
mononuclear cells, including pDCs, mDCs, and CD4
+ cells. In
contrast, staining for pDCs, mDCs, STAT1, and dermal ISG15
gave no appreciable signal in skin from healthy donors; however,
CD4
+ cells were rarely observed in the sections of normal skin
examined. CD31 was used as a positive tissue control, to
demonstrate that expressed epitopes in the skin cryosections could
be detected by immunohistochemical staining (Figure 9).
Discussion
Type I IFNs are produced in response to viral and bacterial
infections and play a key role in host defense mechanisms. They
stimulate thematurationofpDCsand thegenerationandfunction of
natural killer (NK), T, and B cells [16,17]. The type I IFN family is
composed of several family members (13 IFN-a subtypes, IFN-b,- v,
-k,- s,- d,- l); IFN-a and IFN-b are the most abundant. IFN-c,a
type II IFN, is mainly produced by activated T cells, dendritic cells,
and NK cells and is involved in adaptive immune responses.
IFNs have long been associated with the pathogenesis of
psoriasis. IFN pathways are active in psoriatic lesions [18,19].
Treatment of non-psoriatic disease with IFN can induce or
exacerbate psoriasis [20–23], as can treatment with imiquimod, a
toll-like receptor agonist that induces production of type I IFNs
from pDCs [24]. Constitutive IFN-a/b signaling in mice lacking
IFN regulatory factor-2 induces a psoriasis-like inflammatory skin
disease [25]. A direct functional role of IFN-a/b in psoriasis
initiation was recently demonstrated in a xenograft murine model
of human psoriasis, where nonlesional skin from psoriatic patients
was transplanted onto immunocompromised mice [26]. Disrup-
tion of IFN-a signaling or the inhibition of the ability of pDCs to
produce IFN-a prevented the T cell–dependent development of
psoriasis,[26]. Thus, pDC-derived IFN-a is both necessary and
sufficient for disease manifestation in this model; however,
confirmatory human data is lacking.
Microarray analysis of disease tissues has widely been used to
identify etiopathogenic factors of disease activity, and previous
studies have used microarray analyses to profile lesional skin and
nonlesional skin from psoriatic patients [7,27]. However, neither
of these studies was performed using a whole genome array
platform. Furthermore, the first study lacked skin from healthy
donors as a control and was carried out on a limited number of
patient samples. The second study focused mainly on T cell and
dendritic cell activation in lesional skin of psoriatic patients.
The data described here represent the first large-scale study on
human samples that demonstrates the prevalence of type I IFNs
and type I IFN–inducible genes in psoriatic skin. We show that (1)
mRNAs of type I IFN family members are up-regulated in lesional
skin but not in nonlesional skin (except IFN-a5 and IFN-k); (2)
IFN-a/b signaling pathway is the most significantly activated
pathway in lesional skin compared with both nonlesional skin and
skin from healthy donors; (3) there is a prevalent and robust
overexpression of a large panel of type I IFN–inducible genes in
lesional skin (but not in nonlesional skin) of the majority of the
psoriatic patients examined in the study; (4) pDCs, the natural
IFN-a/b–producing cells are present in lesional skin; and (5)
ISG15 and STAT1, 2 type I IFN–inducible proteins, are
overexpressed in lesional skin of psoriatic patients.
OfthetypeIIFN–induciblegenesoverexpressedinlesionalskinof
psoriatic patients, STAT1 is a key component in forming the ISGF3
complex. ISGF3 is the heterotrimeric transcriptional factor complex
that is formed upon the activation of the type I IFN receptor. It is
composed of phosphorylated STAT1, STAT2, and IRF9. Upon
translocation to the nucleus, this complex is capable of activating the
transcription of type I IFN–inducible genes [28]. IRF7 is the master
regulator of the IFN-a/b mediated immune response, and MYD88
and IRF7 govern the induction of CD8
+ Tc e l lr e s p o n s e s[ 2 9 , 3 0 ] .
IRF1 functions as a transcriptional activator for the type I IFN–
induciblegenes[31].MX1,MX2,and OASfamilymembersOAS1,
Figure 9. Immunohistochemical analyses of biopsies from psoriatic lesional and nonlesional skin and skin from normal donors.
BDCA2 is a specific marker for pDCs, which are present at greater numbers in lesional skin (inset is 1006) compared with nonlesional skin, and not at
all in skin from healthy donors. CD83 is a marker for mDCs; CD4 is present on T cells and dendritic cells. STAT1 protein staining was observed in the
epidermis of lesional skin (both nuclear and cytoplasmic) and dermal mononuclear inflammatory cells, but not in nonlesional or skin from healthy
donors. ISG15 protein increase was observed in psoriatic lesional skin and to a lesser extent in nonlesional skin but was not detected in the dermis of
healthy donors. A positive tissue control (CD31) and an assay control (21u) was included that eliminated the primary antibody from the
immunohistochemical assay.
doi:10.1371/journal.pone.0002737.g009
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ubiquitin-like protein that becomes conjugated to many cellular
proteins upon activation by IFN-a/b [32]. USP18, UBE2L6, and
HERC5 are all members of the ISG15 signaling pathways. LAMP3
and CD83 are dendritic cell–marker genes.
Besides the prevalence of overexpression of type I IFN–inducible
genes and proteins in lesional skin, we observed leukocyte infiltration
(CD4
+ Tc e l l s ,C D 8 3
+ mDCs, and neutrophils; data not shown) in
the dermis and epidermis of lesional skin as well as overexpression of
genes that are T cell and dendritic cell markers and those that are
involvedinTcelltrafficking.WealsoshowedthatmRNAsofTNF-a
and TNF-a–inducible genes are overexpressed in lesional skin of
psoriatic patients, which may shed light on why anti–TNF-a therapy
provides clinical benefit to psoriatic patients. The overexpression of
an array of proinflammatory cytokines and/or their inducible genes
(TNF-a,I F N - c, IL-1, IL-8, IL-15, IL-17,IL-19,IL-23, and OSM)in
lesional skin suggests that they might be involved in the pathogenesis
of the disease.
Type I IFNs may provide the link between innate and adaptive
immune responses. They are secreted by pDCs in response to
environmental factors like mechanical stress and infections of the
skin (2 of the common triggers that cause disease relapse),and drive
the activation and expansion of pathogenic T cells leading to
psoriasis [24,26]. Our observations support this link. For example,
the presence of pDCs and mDCs and the up-regulation of mRNAs
of type I IFN members in lesional skin suggest the overexpression of
typeIIFNproteinsatthesesites.TypeIIFNscanfacilitateactivation
of mDCs and promote T cell polarization to proinflammatory Th1
effectors [33]. We observed enrichment of mDCs and CD4
+ Tc e l l s ,
as well as the overexpression of IFN-c–inducible genes in lesional
skin of psoriatic patients. The mRNA for IL-8, a key chemoat-
tractant for neutrophils, and IFN-c and TNF-a–inducible genes are
not overexpressed in nonlesional skin compared with skin from
healthy donors. However, all of these genes are overexpressed in
lesional skin in a similar manner to the overexpression of mRNAs of
type I IFN family members and type I IFN–inducible genes. It
remains unclear as to whether IFN-a signaling occurs upstream or
downstream of IFN-c and TNF-a signaling. Ongoing genomic
studies for anti IFN-a mAb trial in psoriasis from our laboratory will
clarify this issue in the near future.
Type I IFN has been implicated to be involved in the
pathogenesis of other autoimmune diseases like systemic lupus
erythematosus (SLE), type I diabetes, rheumatoid arthritis,
myositis, and Sjo ¨gren’s syndrome [34–36]. The present study
demonstrates the utility of analysis of tissues from disease sites
using microarray and immunohistochemistry to unveil potential
mediators of the pathogenesis of psoriasis. This approach has been
successfully used to show the involvement of type I IFNs in the
pathogenesis of SLE and myositis [35,37,38]. The identification of
significant overexpression of mRNA of TNF-a and TNF-a–
inducible genes in lesional skin of psoriatic patients and the
therapeutic benefit of anti–TNF-a therapies in psoriasis provide
further support of using the microarray approach to identify
potential therapeutic targets for diseases. The presence of type I
IFN–producing pDCs, overexpression of mRNAs of type I IFNs
and type I IFN–inducible genes and proteins in lesional skin of
psoriatic patients provide a strong rationale for investigating type I
IFNs as new therapeutic targets for the treatment of psoriasis.
Materials and Methods
Patients and Controls
A total of 21 biopsies from healthy donors (5 samples were
obtained from Biochain, 14 samples were from ILSBio, and 2
samples were from Dr. James Krueger, Rockefeller University,
New York, NY), 26 paired nonlesional and lesional (all were
plaque-type) skin biopsies from 26 psoriatic patients (21 pairs from
Asterand, 5 pairs from Dr. Krueger), and 5 lesional skin biopsies
from 3 psoriatic patients (all plaque-type) were profiled using the
AffymetrixH whole genome array. Of these, 3 nonlesional skin
samples either did not yield sufficient cRNA or the scanned arrays
had high scaling factors (.2-fold higher than the average) and
were excluded from data analysis. All the donors who gave biopsy
tissue (both healthy controls and individuals with psoriasis) gave
written informed consent for the tissue to be taken and used in this
study. Human specimens used in this paper that were procured
from both registered commercial vendors and Dr. Krueger at
Rockefeller University obtained IRB approval from their respec-
tive branches to collect samples.
Ex vivo stimulation of whole blood from healthy donors
Ex vivo stimulation of whole blood was conducted on blood
collected from 3 or 4 donors (MedImmune, Inc.). Blood samples
were exposed to treatments of vehicle (16PBS), a panel of IFN-a
subtypes (IFN-a2a, -4b, -5, -6, -7, -8, -10, -16, -17), IFN-b, IFN-v,
IFN-l, IFN-c, leukocyte IFN, or TNF-a at concentration of
3xEC50. TNF-a and IFN-c were purchased from R&D Systems
(Minneapolis, MN) and the rest of the cytokines were purchased
from PBL Biomedical (Piscataway, NJ). Following dosing, the
blood was incubated at 37uC, 5% CO2 for 4 hours and transferred
to a PAXgene RNA tube and inverted 8 to 10 times. The
PAXgene tubes were incubated at room temperature for 2 hours
and then frozen until processed. All the blood donors gave written
informed consent for the blood to be taken and used in this study.
In vitro stimulation of normal human keratinocytes with
type I IFN
Normal human keratinocytes (EpiDerm system, MatTek, Inc.)
were grown under serum-free conditions according to manufac-
turer’s instructions and stimulated with either human leukocyte
IFN (150 IU/ml, PBL Biomedical Labs), or human IFNa-2a
(350 IU/ml, PBL Biomedical Labs). Epidermal cultures were
harvested at 4 hours post-treatment for transcript analysis.
Total RNA extraction and microarray processing
Total RNA was extracted from PAXgene blood and skin
biopsies using the PAXgene Blood RNA kit and the Qiagen
RNeasy Fibrous Tissue Mini kit (Hilden, Germany), respectively.
RNA purity and concentration were determined spectrophoto-
metrically (260/280.1.9). RNA quality was assessed on an
Agilent 2100 Bioanalyzer using the RNA 6000 Nano LabChipH.
The generation of biotin-labeled amplified cRNA from 2 mgo f
total RNA was accomplished with the Affymetrix GeneChipH
One-Cycle cDNA Synthesis kit and the Affymetrix GeneChipH
IVT Labeling kit. The concentration and purity of the cRNA
product were determined spectrophotometrically. Twenty micro-
grams of each biotin-labeled cRNA was fragmented for hybrid-
ization on Affymetrix Human Genome U133 Plus 2.0 GeneChipH
arrays. All GeneChipH washing, staining, and scanning procedures
were performed with Affymetrix standard equipment. Data
capture and initial array quality assessments were performed with
the GeneChip Operating Software (GCOS) tool.
Microarray data analysis
Stratagene’s (La Jolla, CA) ArrayAssistH Lite software was used
to calculate probe-level summaries (GC-RMA) from the array
CEL files. R packages (R Development Core Team) samr and
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and hierarchical clustering analyses were performed with SpotFire
(http://www.spotfire.com/) and R packages. Pathway and
network analyses of gene expression data were conducted with
the MetaCore
TM integrated software suite from GeneGo, Inc. (St.
Joseph, MI). The microarray data reported in this manuscript is
MIAME-compliant and is available at: http://www.medimmune.
com/translationalscience/data/psoriasis2007/.
All authors in the manuscript have access to all data and act as
guarantor for the analysis and the manuscript overall.
Applied Biosystems’s TLDA
TLDA from Applied Biosystems was used to determine the fold-
change differential for a panel of genes between paired lesional
skin and nonlesional skin from psoriatic patients. Genes printed on
the array included 9 type I IFN-a subtypes (1, 2, 5, 6, 7, 8, 14, 17,
and 21), 3 additional type I IFNs (IFN-b,- k,- v), IFN-c, IFNAR1,
IFNAR2, IFNGR1, IFNGR2, and TNF-a. Double-stranded
cDNA for each patient sample was preamplified for 10 cycles
using the TaqMan PreAmp Master Mix kit (Applied Biosystems).
Standard procedures for loading the array were then followed and
the array was run on a 7900HT Fast Real-Time PCR System
(Applied Biosystems). Data analysis of the resulting Ct values was
conducted with SDSv2.2.2 software (Applied Biosystems).
Fluidigm’s Biomark system
Preamplification of cDNA and real-time PCR. A mixture
of 43 TaqMan Gene Expression assays (Applied Biosystems) was
prepared (18S not included) using the TaqMan PreAmp Master
Mix Kit (Applied Biosystems). A total of 44 samples were run in
triplicate (using 3 different BioMark Real-Time PCR Systems)
against a set of 48 TaqMan Gene Expression Assays in BioMark
48.48 Dynamic Array chips (Fluidigm Corp). The normal controls
were included on every array. Three identical dynamic arrays
were prepared in parallel for each set of 16 samples totaling 9
dynamic arrays. Dynamic arrays were loaded using a NanoFlex 4-
IFC Controller (Fluidigm Corp), and real-time reactions were
performed and analyzed using BioMark Real-Time PCR System
and Analysis software (Fluidigm Corp), respectively. SDs were
calculated for each set of 3 replicate reactions and then averaged
for each dynamic array. Cts above 20 were excluded from the
calculation. Delta-delta Cts (DDCt) were calculated using the
mean of the 4 reference genes (GAPDH, TFRC, b2M, and 18S)
and a calibrator sample and were converted to fold expression
change by the following formula: 2
2DDCt.
Immunohistochemistry
One half of each frozen psoriatic, nonlesional, and healthy
donor biopsy was embedded in optimum cutting temperature
(OCT) compound sectioned at 5 mm, mounted on charged slides
(Mercedes Medical, FL), and fixed in cold acetone. Incubation
with primary antibodies was performed as follows: BDCA-2
(Miltenyi Biotec, Auburn, CA) at a 1:5 dilution for 5 hours,
STAT1 (Abcam, Cambridge, MA) at a 1:100 dilution for 4 hours,
CD83 (Immunotech, Fullerton, CA) at a 1:300 dilution for
1.5 hours, ISG15 (Abcam, Cambridge, MA) at a 1:25 dilution for
2 hours, and CD4 (DakoCytomation, Carpenteria, CA) at a 1:20
dilution for 1 hour. CD31 (BD Biosciences Pharmingen, San Jose,
CA, at 1 mg/mL and incubated for 2 hours) was used as a positive
tissue control. The slides were washed and incubated with
peroxidase-labeled polymer conjugated to goat anti-mouse
immunoglobulin antibody (Envision+; DakoCytomation, Carpen-
teria, CA) for 30 minutes, then washed with tris-buffered saline
(pH 7.2). Detection was performed with 3,39-diaminobenzidine
tetrahydrochloride (DAB+; DakoCytomation) as the chromogen.
Slides were counterstained with hematoxylin, dehydrated, and
cover slipped.
Online supplemental material
Figure S1 shows hierarchical clustering of 1384 probe sets
differentially regulated by IFN-a subtypes, IFN-b, IFN-c, and
TNF-a in whole blood ex vivo stimulation experiment. Table S1
lists the top 100 probe sets up-regulated in lesional skin compared
with nonlesional skin in psoriasis. Table S2 lists the top 50 probe
sets down-regulated in lesional skin compared with nonlesional
skin in psoriasis. Table S3 lists the top 50 probe sets down-
regulated in nonlesional skin compared with skin from healthy
donors. Table S4 lists the top 50 probe sets up-regulated from the
in vitro stimulation of normal human keratinocytes with leukocyte
IFN. Online supplemental material is available at http://www.
medimmune.com/translationalscience/data/psoriasis2007.
Supporting Information
Table S1 Fold change (fc; log2 transformed) and q Value
(calculated by FDR) of the top 100 probe sets up-regulated in
lesional skin compared with nonlesional skin in psoriasis. Also
listed are the log2 transformed fold change and q values of these
genes when comparing nonlesional skin with normal skin from
healthy donors. Type I IFN-inducible genes are designated by the
IFNI column. The table is available at: http://www.medimmune.
com/translationalscience/data/psoriasis2007/.
Found at: doi:10.1371/journal.pone.0002737.s001 (0.04 MB
DOC)
Table S2 Fold change (fc; log2 transformed) and q Value
(calculated by FDR) of the top 50 probe sets down-regulated in
lesional skin compared with nonlesional skin in psoriasis. Also
listed are the log2 transformed fold change and q Values of these
genes when comparing nonlesional skin with normal skin from
healthy donors. All data was GC-RMA normalized. The table is
available at: http://www.medimmune.com/translationalscience/
data/psoriasis2007/.
Found at: doi:10.1371/journal.pone.0002737.s002 (0.03 MB
XLS)
Table S3 Fold change (fc; log2 transformed) and q Value
(calculated by FDR) of the top 50 probe sets down-regulated in
nonlesional skin compared with skin from healthy donors. Also
listed are the log2 transformed fold change and q values of these
genes when comparing nonlesional skin with lesional skin. All data
was GC-RMA normalized. The table is available at: http://www.
medimmune.com/translationalscience/data/psoriasis2007/.
Found at: doi:10.1371/journal.pone.0002737.s003 (0.03 MB
XLS)
Table S4 Fold change (fc; log2 transformed), P values, and mean
signal intensities for the top 50 probe sets up-regulated from the in
vitro stimulation of normal human keratinocytes with leukocyte
IFN. Normal human keratinocytes were stimulated with human
leukocyte IFN. Replicates of three were run for both the untreated
samples and the stimulated samples. A paired Student’s t-test
was used to calculate the P values. All data was GC-RMA
normalized. The table is available at: http://www.medimmune.
com/translationalscience/data/psoriasis2007/.
Found at: doi:10.1371/journal.pone.0002737.s004 (0.11 MB
XLS)
Figure S1 Hierarchical clustering of 1384 probe sets differen-
tially regulated by IFN-a subtypes and IFN-b (pink), IFN-c (blue),
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(see Materials and Methods). Each role corresponds to a single
probe set, while each column corresponds to a single sample.
Color represents relative expression level of individual probe set as
compared with the average expression of the no treatment controls
(black). Red represents up-regulation versus control, green down-
regulation versus control, while black indicates no change.
Found at: doi:10.1371/journal.pone.0002737.s005 (0.50 MB TIF)
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